First Generic Of Gilead’s Biktarvy In India Debuts
Executive Summary
Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.
You may also be interested in...
2019 India Deals - Sell, License, Brands And China
Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.
Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.